Covance New Signings Slow In U.S.; Kimbrell Returns To Top At Oread

The discontinuation of a Lilly/Solvay cardiovascular development program in March is showing up with a six-month delay in Covance operating results with spill-over effects on the image and predictability of the CRO segment.